{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:57:43Z","timestamp":1786989463576,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["fsijournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.forsciint.2013.11.009","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T13:14:13Z","timestamp":1385039653000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009\u20132012)"],"prefix":"10.1016","volume":"234","author":[{"given":"Jennifer L.","family":"Pilgrim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Gerostamoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf H.","family":"Drummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.forsciint.2013.11.009_bib0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/11319200-000000000-00000","article-title":"Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies","volume":"33","author":"Brunton","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/14740338.2011.582037","article-title":"Adverse reactions to duloxetine in depression","volume":"10","author":"Bitter","year":"2011","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1517\/14740338.4.6.987","article-title":"Safety and adverse event profile of duloxetine","volume":"4","author":"Wernicke","year":"2005","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e31821b3aa0","article-title":"Serotonin syndrome due to duloxetine","volume":"34","author":"Gelener","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0025","first-page":"581","article-title":"Serotonin syndrome induced by duloxetine","volume":"43","author":"Hadikusumo","year":"2009","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0030-1268420","article-title":"Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine \u2013 case report","volume":"44","author":"Himmighoffen","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0035","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.4088\/JCP.v67n1122f","article-title":"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome","volume":"67","author":"Jimenez-Genchi","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0040","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1532-5415.2009.02601.x","article-title":"Serotonin syndrome in an octogenarian after switch from fluoxetine to duloxetine","volume":"57","author":"Liu","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0045","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cgh.2006.04.018","article-title":"Case report: fulminant hepatic failure involving duloxetine hydrochloride","volume":"4","author":"Hanje","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12012-012-9159-x","article-title":"Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine: a case report","volume":"12","author":"Mari","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15622970701586331","article-title":"Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines","volume":"10","author":"Menchetti","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jflm.2010.02.002","article-title":"Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey","volume":"17","author":"Vey","year":"2010","journal-title":"J. Forensic Leg. Med."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jat\/18.3.134","article-title":"Capillary gas chromatographic drug screen for use in forensic toxicology","volume":"18","author":"Drummer","year":"1994","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0070","series-title":"Micromedex\u00ae Healthcare Series","author":"Thomson Reuters (Healthcare) Inc.","year":"1974"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0075","series-title":"Expenditure and prescriptions twelve months to 20 June 2012","author":"Data and Modelling Section Pharmaceutical Policy and Analysis Branch","year":"2012"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0080","series-title":"Expenditure and prescriptions twelve months to June 2008","author":"Data and Modelling Section Pharmaceutical Policy and Analysis Branch","year":"2008"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0085","series-title":"Australian Statistics on Medicines 2009","author":"Department of Health and Ageing A","year":"2011"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jat\/30.8.576","article-title":"A first look at duloxetine (Cymbalta) in a postmortem laboratory","volume":"30","author":"Anderson","year":"2006","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00023210-199504020-00001","article-title":"Selective serotonin\/noradrenal reuptake inhibitors (SNRIs)","volume":"4","author":"Artigas","year":"1995","journal-title":"CNS Drugs"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.NURSE.0000428705.58507.3d","article-title":"Neuroleptic malignant syndrome","volume":"43","author":"Vacca","year":"2013","journal-title":"Nursing"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0105","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/jpm.2006.9.1257","article-title":"A case of serotonin syndrome and mutism associated with methadone","volume":"9","author":"Bush","year":"2006","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/bja\/aei210","article-title":"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity","volume":"95","author":"Gillman","year":"2005","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2010","journal-title":"Forensic Sci. Med. Pathol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1345\/aph.1A302","article-title":"Severe serotonin syndrome induced by mirtazapine monotherapy","volume":"36","author":"Hernandez","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1345\/aph.1D344","article-title":"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine","volume":"38","author":"Houlihan","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1345\/aph.1E671","article-title":"Serotonin syndrome induced by fluvoxamine and oxycodone","volume":"40","author":"Karunatilake","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0135","series-title":"Product Information: Cymbalta\u00ae oral capsules (30mg and 60mg duloxetine hydrochloride)","author":"Eli Lilly Australia Pty Limited","year":"2011"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/14656566.7.2.215","article-title":"Duloxetine in diabetic neuropathy","volume":"7","author":"Smith","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0145","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/PL00000897","article-title":"Cytochromes P450 and metabolism of xenobiotics","volume":"58","author":"Anzenbacher","year":"2001","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jclinane.2011.04.017","article-title":"A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion","volume":"24","author":"Gollapudy","year":"2012","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0155","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1017\/S1461145709990484","article-title":"Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt","volume":"12","author":"Paulzen","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00007691-200204000-00002","article-title":"Postmortem drug analysis: analytical and toxicological aspects","volume":"24","author":"Drummer","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0165","article-title":"Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma","author":"Launiainen","year":"2013","journal-title":"Drug Test Anal."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.jcp.0000155815.44338.95","article-title":"Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine","volume":"25","author":"Thase","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0175","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1600-0447.2008.01260.x","article-title":"Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety","volume":"118","author":"Taylor","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hup.696","article-title":"Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials","volume":"20","author":"Hudson","year":"2005","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jpsychires.2007.01.008","article-title":"A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder","volume":"42","author":"Perahia","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0190","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0195","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2174\/1381612043383872","article-title":"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns","volume":"10","author":"Pacher","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12024-012-9404-4","article-title":"The toxicology and comorbidities of fatal cases involving quetiapine","volume":"9","author":"Pilgrim","year":"2013","journal-title":"Forensic Sci. Med. Pathol."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0205","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1360-0443.2009.02565.x","article-title":"Drugs and violent death: comparative toxicology of homicide and non-substance toxicity suicide victims","volume":"104","author":"Darke","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.psc.2013.02.004","article-title":"Antidepressant Overdose-induced Seizures","volume":"36","author":"Judge","year":"2013","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.forsciint.2013.11.009_bib0215","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/00048679609076098","article-title":"Antidepressant deaths by overdose","volume":"30","author":"Battersby","year":"1996","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0220","series-title":"Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA","first-page":"75","article-title":"Statistical Evaluation of Suicidality in Adults Treated with Antidepressants","author":"Levenson","year":"2006"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0225","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.npp.1300996","article-title":"The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children","volume":"31","author":"Klein","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0230","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/appi.ajp.2007.07030454","article-title":"Early evidence on the effects of regulators\u2019 suicidality warnings on SSRI prescriptions and suicide in children and adolescents","volume":"164","author":"Gibbons","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0235","series-title":"Report of the Psychiatric Drug Safety Expert Advisory Panel","author":"Therapeutic Goods Administration (TGA)","year":"2009"},{"key":"10.1016\/j.forsciint.2013.11.009_bib0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/jcp.0b013e318160d5c3","article-title":"Suicidal ideation associated with duloxetine use: a case series","volume":"28","author":"Parikh","year":"2008","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Forensic Science International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073813004957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073813004957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T17:51:31Z","timestamp":1539021091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0379073813004957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":48,"alternative-id":["S0379073813004957"],"URL":"https:\/\/doi.org\/10.1016\/j.forsciint.2013.11.009","relation":{},"ISSN":["0379-0738"],"issn-type":[{"value":"0379-0738","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009\u20132012)","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.forsciint.2013.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}